PARSIPPANY, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S.
Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly prescribed once-a-week injection to manage diabetes) in lowering blood sugar levels, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback